{"id":65548,"date":"2026-05-18T13:32:07","date_gmt":"2026-05-18T05:32:07","guid":{"rendered":"https:\/\/flcube.com\/?p=65548"},"modified":"2026-05-18T13:32:08","modified_gmt":"2026-05-18T05:32:08","slug":"roches-tecentriq-secures-fda-approval-for-ctdna-guided-adjuvant-treatment-in-muscle-invasive-bladder-cancer-first-mrd-directed-immunotherapy-with-41-mortality-reduction","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65548","title":{"rendered":"Roche&#8217;s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction"},"content":{"rendered":"\n<p><strong>Roche AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ROP:SWX\">SWX: ROP<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved <strong>Tecentriq (atezolizumab)<\/strong> and <strong>Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)<\/strong> as adjuvant treatment for <strong>adult patients with muscle-invasive bladder cancer (MIBC)<\/strong> who have <strong>circulating tumor DNA molecular residual disease (ctDNA MRD)<\/strong> following cystectomy, as detected by <strong>Natera&#8217;s Signatera CDx personalized MRD assay<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (United States)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full marketing authorization with companion diagnostic<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td>Tecentriq (IV) and Tecentriq Hybreza (subcutaneous)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adjuvant treatment of MIBC with ctDNA MRD post-cystectomy<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>15 May 2026<\/td><\/tr><tr><td><strong>Companion Diagnostic<\/strong><\/td><td>Natera Signatera CDx personalized MRD assay<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-innovation\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Atezolizumab \u2013 monoclonal antibody targeting PD-L1<\/li>\n\n\n\n<li><strong>Formulations:<\/strong> Intravenous (Tecentriq) and subcutaneous (Tecentriq Hybreza)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First <strong>ctDNA-guided adjuvant immunotherapy<\/strong> approval in bladder cancer<\/li>\n\n\n\n<li><strong>Therapeutic Paradigm:<\/strong> Precision medicine approach using molecular residual disease detection to identify high-risk patients most likely to benefit from adjuvant therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-imvigor011-phase-3-trial\">Clinical Evidence \u2013 IMvigor011 Phase 3 Trial<\/h2>\n\n\n\n<p>The approval was based on the <strong>Phase 3 IMvigor011 study<\/strong>, which demonstrated unprecedented survival benefits in the ctDNA MRD-positive population:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (Tecentriq)<\/th><th>Benefit vs. Placebo<\/th><\/tr><\/thead><tbody><tr><td><strong>Disease-Free Survival (DFS)<\/strong><\/td><td>36% risk reduction<\/td><td>HR 0.64 (95% CI: 0.47-0.87)<\/td><\/tr><tr><td><strong>Overall Survival (OS)<\/strong><\/td><td>41% risk reduction<\/td><td>HR 0.59 (95% CI: 0.41-0.85)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>ctDNA MRD-positive within 1 year post-cystectomy<\/td><td>Serial testing required for identification<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Consistent with previous Tecentriq studies<\/td><td>No new safety signals identified<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-unmet-need\">Market Context &amp; Unmet Need<\/h2>\n\n\n\n<p><strong>Muscle-invasive bladder cancer<\/strong> affects approximately <strong>20,000-25,000 patients annually in the US<\/strong>, with <strong>50-60% recurrence rate<\/strong> following radical cystectomy. Traditional adjuvant chemotherapy provides limited benefit and significant toxicity, while many patients receive no adjuvant therapy due to uncertain risk stratification.<\/p>\n\n\n\n<p><strong>The ctDNA-guided approach addresses critical gaps:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Identifies <strong>high-risk patients<\/strong> most likely to benefit from adjuvant immunotherapy<\/li>\n\n\n\n<li>Spares <strong>low-risk patients<\/strong> from unnecessary treatment and associated toxicities<\/li>\n\n\n\n<li>Provides <strong>molecular-level monitoring<\/strong> capability through serial ctDNA testing<\/li>\n\n\n\n<li>Enables <strong>earlier intervention<\/strong> at molecular relapse before clinical manifestation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-implications\">Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Strategy:<\/strong> Premium pricing expected for both IV and subcutaneous formulations, reflecting survival benefit and precision medicine value<\/li>\n\n\n\n<li><strong>Market Penetration:<\/strong> Initial focus on academic medical centers and comprehensive cancer centers with ctDNA testing capabilities<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Establishes Tecentriq as the <strong>first and only<\/strong> FDA-approved adjuvant immunotherapy for ctDNA MRD-positive MIBC<\/li>\n\n\n\n<li><strong>Diagnostic Partnership:<\/strong> Exclusive relationship with Natera creates integrated therapeutic-diagnostic ecosystem<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Oncology Leadership:<\/strong> Reinforces Roche&#8217;s commitment to biomarker-driven cancer immunotherapy development<\/li>\n\n\n\n<li><strong>ctDNA Validation:<\/strong> Represents one of the first regulatory approvals based on circulating tumor DNA as a predictive biomarker<\/li>\n\n\n\n<li><strong>Subcutaneous Advantage:<\/strong> Tecentriq Hybreza offers improved patient convenience and reduced healthcare resource utilization versus IV administration<\/li>\n\n\n\n<li><strong>Platform Potential:<\/strong> Success may support expansion to other tumor types using ctDNA MRD as a selection criterion<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial performance for Tecentriq and Tecentriq Hybreza. Actual results may differ due to risks including market adoption rates, competitive dynamics, and reimbursement decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration (FDA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65550,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[940,18,15,163,939],"class_list":["post-65548","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-otcmkts-rhhby","tag-pd-1-l1","tag-product-approvals","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche&#039;s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) following cystectomy, as detected by Natera&#039;s Signatera CDx personalized MRD assay.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65548\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche&#039;s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction\" \/>\n<meta property=\"og:description\" content=\"Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) following cystectomy, as detected by Natera&#039;s Signatera CDx personalized MRD assay.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65548\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-18T05:32:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-18T05:32:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1802.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65548#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65548\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche&#8217;s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction\",\"datePublished\":\"2026-05-18T05:32:07+00:00\",\"dateModified\":\"2026-05-18T05:32:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65548\"},\"wordCount\":493,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65548#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1802.webp\",\"keywords\":[\"OTCMKTS: RHHBY\",\"PD-1\\\/L1\",\"Product approvals\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65548#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65548\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65548\",\"name\":\"Roche's Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65548#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65548#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1802.webp\",\"datePublished\":\"2026-05-18T05:32:07+00:00\",\"dateModified\":\"2026-05-18T05:32:08+00:00\",\"description\":\"Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) following cystectomy, as detected by Natera's Signatera CDx personalized MRD assay.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65548#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65548\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65548#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1802.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1802.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche's Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65548#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche&#8217;s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche's Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction - Insight, China&#039;s Pharmaceutical Industry","description":"Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) following cystectomy, as detected by Natera's Signatera CDx personalized MRD assay.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65548","og_locale":"en_US","og_type":"article","og_title":"Roche's Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction","og_description":"Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) following cystectomy, as detected by Natera's Signatera CDx personalized MRD assay.","og_url":"https:\/\/flcube.com\/?p=65548","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-18T05:32:07+00:00","article_modified_time":"2026-05-18T05:32:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1802.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65548#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65548"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche&#8217;s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction","datePublished":"2026-05-18T05:32:07+00:00","dateModified":"2026-05-18T05:32:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65548"},"wordCount":493,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65548#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1802.webp","keywords":["OTCMKTS: RHHBY","PD-1\/L1","Product approvals","Roche","SWX: ROP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65548#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65548","url":"https:\/\/flcube.com\/?p=65548","name":"Roche's Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65548#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65548#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1802.webp","datePublished":"2026-05-18T05:32:07+00:00","dateModified":"2026-05-18T05:32:08+00:00","description":"Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) as adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) following cystectomy, as detected by Natera's Signatera CDx personalized MRD assay.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65548#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65548"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65548#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1802.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1802.webp","width":1080,"height":608,"caption":"Roche's Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65548#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche&#8217;s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer \u2013 First MRD-Directed Immunotherapy with 41% Mortality Reduction"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1802.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65548"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65548\/revisions"}],"predecessor-version":[{"id":65551,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65548\/revisions\/65551"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65550"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}